Pardes Biosciences, Inc. - Common Stock (NQ:PRDS)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 30, 2023 Add to My Watchlist

Price and Volume

Volume	0
Open	-
Bid (Size)	2.160 (5)
Ask (Size)	2.210 (250)
Prev. Close	2.160
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	61,716,745
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences

August 28, 2023

From Foresite Capital

Via Business Wire

MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares

August 17, 2023

From MediPacific, Inc.

Via Business Wire

Performance

More News

PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS

August 07, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Why Pardes Biosciences Shares Are Rising Monday ↗

July 17, 2023

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sculptor Capital Management Inc. (NYSE – SCU), Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Great Ajax Corp. (NYSE – AJX)

July 24, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS

July 21, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Recap: Pardes Biosciences Q1 Earnings ↗

May 05, 2023

Via Benzinga

Pardes Biosciences Looks For Alternatives After Failed COVID-19 Study ↗

April 03, 2023

Via Benzinga

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

July 19, 2023

From The Schall Law Firm

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023 ↗

July 18, 2023

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Kaleyra, Inc. (NYSE – KLR), Great Ajax Corp. (NYSE – AJX)

July 18, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

PRDS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Pardes Biosciences, Inc. Is Fair to Shareholders

July 17, 2023

From Halper Sadeh LLC

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

April 24, 2023

Via InvestorPlace

Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 17, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 03, 2023

Via Benzinga

Pardes Biosciences, Inc. (NASDAQ:PRDS) Investor Alert: Investigation over Potential Wrongdoing ↗

February 14, 2023

Via SBWire

Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023 ↗

April 04, 2023

Via Benzinga

Investigation Announced for Investors Who Lost Money with Shares of Pardes Biosciences, Inc. (NASDAQ: PRDS) ↗

January 23, 2023

Via SBWire

Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket ↗

December 13, 2022

Via Benzinga

Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 15, 2023

Via Benzinga

Vapotherm, Redwire And These 2 Penny Stocks Insiders Are Aggressively Buying ↗

December 06, 2022

Via Benzinga

Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 31, 2023

Via Benzinga

Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session ↗

December 13, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022 ↗

December 13, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

November 28, 2022

Via Benzinga

Frequently Asked Questions

Is Pardes Biosciences, Inc. - Common Stock publicly traded?

Yes, Pardes Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Pardes Biosciences, Inc. - Common Stock trade on?

Pardes Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Pardes Biosciences, Inc. - Common Stock?

The ticker symbol for Pardes Biosciences, Inc. - Common Stock is PRDS on the Nasdaq Stock Market